FDA Approves Blincyto® (Blinatumomab) in Cd19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All) in the Consolidation Phase
FDA批准Blincyto®（Blinatumomab）在鞏固期治療Cd19陽性、Philadelphia染色體陰性的B細胞前體急性淋巴細胞白血病（B-All）。